Ribonucleic Acid (RNA)-Based Oncolytic Therapy Global Market Report 2025
상품코드:1855975
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
리보핵산(RNA) 종양 용해 치료 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 17억 8,000만 달러로 평가되었고, 2025년에는 21억 2,000만 달러에 이르고, CAGR 18.9%로 성장할 전망입니다. 실적기간의 성장은 암 유병률 증가, 헬스케어 인프라 투자 증가, 표적 치료에 대한 인식 증가, 임상시험 프로그램 확대, 암 연구에 대한 정부 보조금 증가 등에 기인하고 있습니다.
리보핵산(RNA) 종양 용해 치료 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 18.5%로 41억 7,000만 달러로 성장할 전망입니다. 예측기간에서의 성장의 원동력은 RNA 기반 치료법의 채택 확대, 면역종양학에 대한 주목 증가, 생명공학과의 공동연구 증가, 첨단제조시설의 확대, 정밀의료에 대한 접근의 개선입니다. 예측 기간의 주요 동향에는 기술적 진보, 바이러스 벡터 설계의 진보, R&D 투자 증가, 전달 시스템의 혁신, 병용 요법 접근법의 개발 등이 포함됩니다.
맞춤형 의료의 채택 증가는 리보핵산(RNA) 종양 용해 치료 시장의 성장을 가속할 것으로 예측됩니다. 맞춤형 의료는 개인의 유전자 프로파일에 따라 치료를 조정하여 부작용을 최소화하면서 치료 효과를 높이는 것입니다. 이 접근법은 건강 관리 제공업체와 의료 기관이 표적 치료 및 정밀 진단을 통해 환자의 결과를 개선 할 가능성을 인식함에 따라 더 널리 받아 들여지고 있습니다. 리보핵산(RNA) 종양 용해 치료은 맞춤형 의료의 원칙에 따른, 타겟을 좁힌 환자 특이적인 암 치료를 제공하는 것으로, 이 동향을 지지하고 있습니다. 예를 들어, 2024년 2월 미국의 개인화 치료 옹호 단체인 맞춤형 의료 연합(Personalized Medicine Coalition)은 2023년 FDA가 희귀질환 환자를 위한 16개의 신규 개인화 치료를 승인했다고 보고했습니다. 그 결과, 맞춤형 의료의 이용 확대가 리보핵산(RNA) 종양 용해 치료 시장을 전진시키고 있습니다.
리보핵산(RNA) 종양 용해 치료 시장의 주요 기업은 합성 메신저 RNA(mRNA) 등의 기술을 진보시키고 종양 타겟팅을 개선하고 면역 반응을 자극하며 보다 정확하고 지속적인 암 치료 결과를 달성하려고 합니다. 합성 mRNA 기술은 암을 포함한 질병을 치료하기 위해 특정 치료 단백질을 생산하도록 세포에 지시하는 인공 mRNA 서열을 생성하고 전달하는 생명 공학 기술입니다. 예를 들어 2024년 6월 중국 제약회사인 CSPC Pharmaceutical Group Limited는 합성 mRNA 기반 암세포 치료제인 SYS6020의 임상시험 개시 허가를 받았습니다. 이 이정표는 중국의 mRNA 치료 분야에서 중요한 단계입니다. SYS6020은 mRNA-지질 나노입자 기술을 이용하여 부작용을 최소화하면서 골수종 암세포를 선택적으로 공격 파괴하는 것으로, 특정 자가면역질환의 치료에도 유망시되고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 리보핵산(RNA) 종양 용해 치료 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 리보핵산(RNA) 종양 용해 치료 시장 : 성장률 분석
세계의 리보핵산(RNA) 종양 용해 치료 시장 실적 : 규모와 성장, 2019년-2024년
세계의 리보핵산(RNA) 종양 용해 치료 시장 예측 : 규모와 성장, 2024년-2029년, 2034년
세계의 리보핵산(RNA) 종양 용해 치료 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 리보핵산(RNA) 종양 용해 치료 시장 : 치료 유형별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
메신저 리보 핵산(mRNA) 기반 암 용해 요법
소간섭 리보 핵산(siRNA) 기반 암 용해 요법
마이크로 리보 핵산(miRNA) 기반의 암 용해 요법
기타 치료 유형
세계의 리보핵산(RNA) 종양 용해 치료 시장 : 투여 경로별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
정맥 주사
종양내
기타 투여 경로
세계의 리보핵산(RNA) 종양 용해 치료 시장 : 용도별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
유방암
폐암
대장암
전립선암
흑색종
기타 용도
세계의 리보핵산(RNA) 종양 용해 치료 시장 : 최종 사용자별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
병원
암 연구 기관
전문 클리닉
기타 최종 사용자
세계의 리보핵산(RNA) 종양 용해 치료 시장 : 세분화 메신저 리보 핵산(mRNA) 베이스 암 세포 용해 요법, 유형별, 분석과 예측
자기 증폭형 mRNA(saRNA)
비복제 mRNA
원형 RNA(circRNA) 기반 mRNA 요법
세계의 리보핵산(RNA) 종양 용해 치료 시장 : 세분화 소간섭성 리보 핵산(siRNA) 베이스 암 용해 요법, 유형별, 분석과 예측
화학 수식 siRNA
나노입자 전달 siRNA
컨쥬게이트 siRNA
세계의 리보핵산(RNA) 종양 용해 치료 시장 : 세분화 마이크로 리보 핵산(miRNA) 베이스 암 용해 요법, 유형별, 분석과 예측
miRNA 모방체
miRNA 억제제(안타고밀)
miRNA 스폰지 또는 미끼
세계의 리보핵산(RNA) 종양 용해 치료 시장 : 세분화 기타 치료법별별, 분석과 예측
장비암호화 RNA(lncRNA) 기반 치료법
단일 머리핀 RNA(shRNA) 기반 치료법
아프타머 RNA 기반 종양 용해제
제7장 지역별/국가별 분석
세계의 리보핵산(RNA) 종양 용해 치료 시장 : 지역별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
세계의 리보핵산(RNA) 종양 용해 치료 시장 : 국가별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
리보핵산(RNA) 종양 용해 치료 시장 : 경쟁 구도
리보핵산(RNA) 종양 용해 치료 시장 : 기업 프로파일
AstraZeneca PLC : 개요, 제품 및 서비스, 전략 및 재무 분석
Moderna Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
BioNTech SE : 개요, 제품 및 서비스, 전략 및 재무 분석
Gritstone Bio Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Orna Therapeutics Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Strand Therapeutics Inc.
Oncolytics Biotech Inc.
Anima Biotech Inc.
eTheRNA immunotherapies NV
Vyriad Inc.
Haya Therapeutics Inc.
Virogin Biotech Inc.
Providence Therapeutics Holdings Inc.
Sirnaomics Inc.
Humane Genomics Inc.
Replicate Bioscience Inc.
Abogen Biosciences Inc.
Chimeron Bio Inc.
Aro Biotherapeutics Inc.
TransCode Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
리보핵산(RNA) 종양 용해 치료 시장 2029년 : 새로운 기회를 제공하는 국가
리보핵산(RNA) 종양 용해 치료 시장 2029년 : 새로운 기회를 제공하는 부문
리보핵산(RNA) 종양 용해 치료 시장 2029년 : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
Ribonucleic acid (RNA)-based oncolytic therapy is a cancer treatment that employs engineered RNA viruses to selectively infect and destroy tumor cells. These viruses replicate within cancer cells, leading to cell death and the release of tumor antigens. This process also activates the immune system to target remaining cancer cells, enhancing overall anti-tumor effectiveness.
The primary therapy types of ribonucleic acid (RNA)-based oncolytic therapy are messenger RNA (mRNA)-based oncolytic therapy, small interfering RNA (siRNA)-based oncolytic therapy, micro RNA (miRNA)-based oncolytic therapy, and other therapy types. Messenger RNA (mRNA)-based oncolytic therapy involves using synthetic mRNA molecules designed to stimulate the immune system or directly induce tumor cell death, providing a targeted and adaptable approach to cancer treatment. These therapies are administered via intravenous, intratumoral, and other routes, and are applied in breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other indications. Key end-users include hospitals, cancer research institutes, specialty clinics, and related healthcare facilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The ribonucleic acid (RNA)-based oncolytic therapy market research report is one of a series of new reports from The Business Research Company that provides ribonucleic acid (RNA)-based oncolytic therapy market statistics, including the ribonucleic acid (RNA)-based oncolytic therapy industry global market size, regional shares, competitors with the ribonucleic acid (RNA)-based oncolytic therapy market share, detailed ribonucleic acid (RNA)-based oncolytic therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the ribonucleic acid (RNA)-based oncolytic therapy industry. This ribonucleic acid (RNA)-based oncolytic therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The ribonucleic acid (RNA)-based oncolytic therapy market size has grown rapidly in recent years. It will grow from $1.78 billion in 2024 to $2.12 billion in 2025 at a compound annual growth rate (CAGR) of 18.9%. The growth in the historic period is attributed to the increasing prevalence of cancer, rising investment in healthcare infrastructure, growing awareness of targeted therapies, expansion of clinical trial programs, and higher government funding for oncology research.
The ribonucleic acid (RNA)-based oncolytic therapy market size is expected to see rapid growth in the next few years. It will grow to $4.17 billion in 2029 at a compound annual growth rate (CAGR) of 18.5%. The growth in the forecast period is driven by greater adoption of RNA-based therapies, increased focus on immuno-oncology, rising biotechnology collaborations, expansion of advanced manufacturing facilities, and improved access to precision medicine. Key trends in the forecast period include technological advancements, progress in viral vector design, increased investment in research and development, innovation in delivery systems, and the development of combination therapy approaches.
The increasing adoption of personalized medicine is expected to drive growth in the RNA-based oncolytic therapy market. Personalized medicine involves tailoring medical treatments according to an individual's genetic profile, which enhances treatment effectiveness while minimizing side effects. This approach is being embraced more widely as healthcare providers and institutions recognize its potential to improve patient outcomes through targeted therapies and precise diagnostics. RNA-based oncolytic therapy supports this trend by providing targeted, patient-specific cancer treatments that align with personalized medicine principles. For example, in February 2024, the Personalized Medicine Coalition, a United States-based advocacy organization for tailored treatments, reported that the FDA approved sixteen new personalized therapies for rare disease patients in 2023, a notable increase from six approvals in 2022. Consequently, the growing use of personalized medicine is propelling the RNA-based oncolytic therapy market forward.
Leading companies in the RNA-based oncolytic therapy market are advancing technologies such as synthetic messenger RNA (mRNA) to improve tumor targeting, stimulate immune responses, and achieve more precise and lasting cancer treatment results. Synthetic mRNA technology is a biotech method that creates and delivers artificial mRNA sequences to instruct cells to produce specific therapeutic proteins to treat diseases, including cancer. For example, in June 2024, CSPC Pharmaceutical Group Limited, a pharmaceutical company based in China, received regulatory clearance to begin clinical trials of SYS6020, a synthetic mRNA-based cancer cell therapy. This milestone marks a significant step in China's mRNA therapeutic field. SYS6020 uses mRNA-lipid nanoparticle technology to selectively attack and destroy myeloma cancer cells with minimal side effects, and it shows promise for treating certain autoimmune disorders.
In June 2023, Charles River Laboratories International, Inc., a US contract research organization, formed a strategic partnership with Curigin Co., Ltd. to develop oncolytic RNA interference (RNAi) gene therapies. The collaboration aims to accelerate the development and production of Curigin's RNAi-based oncolytic gene therapies by utilizing Charles River's contract development and manufacturing expertise to support both preclinical and clinical studies. Curigin Co., Ltd. is a South Korea-based biotech firm specializing in RNAi oncolytic gene therapies for cancer treatment.
Major players in the ribonucleic acid (RNA)-based oncolytic therapy market are AstraZeneca PLC, Moderna Inc., BioNTech SE, Gritstone Bio Inc., Orna Therapeutics Inc., Strand Therapeutics Inc., Oncolytics Biotech Inc., Anima Biotech Inc., eTheRNA immunotherapies NV, Vyriad Inc., Haya Therapeutics Inc., Virogin Biotech Inc., Providence Therapeutics Holdings Inc., Sirnaomics Inc., Humane Genomics Inc., Replicate Bioscience Inc., Abogen Biosciences Inc., Chimeron Bio Inc., Aro Biotherapeutics Inc., TransCode Therapeutics Inc.
North America was the largest region in the ribonucleic acid (RNA)-based oncolytic therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ribonucleic acid (RNA)-based oncolytic therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the ribonucleic acid (RNA)-based oncolytic therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The ribonucleic acid (RNA)-based oncolytic therapy market includes revenues earned by entities through services such as clinical trials, tumor targeting, immune monitoring, patient support, and treatment administration. The market value includes the value of related goods sold by the service provider or included within the service offering. The ribonucleic acid (RNA)-based oncolytic therapy market also includes sales of RNA oncolytic viruses, viral vectors, delivery systems, formulations, and diagnostic kits. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Ribonucleic Acid (RNA)-Based Oncolytic Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on ribonucleic acid (rna)-based oncolytic therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for ribonucleic acid (rna)-based oncolytic therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ribonucleic acid (rna)-based oncolytic therapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Therapy Type: Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy; Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy; Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy; Other Therapy Types
2) By Route Of Administration: Intravenous; Intratumoral; Other Route Of Administrations
3) By Application: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Other Applications
4) By End-User: Hospitals; Cancer Research Institutes; Specialty Clinics; Other End-Users
3. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Trends And Strategies
4. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Growth Analysis And Strategic Analysis Framework
5.1. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous
Intratumoral
Other Route Of Administrations
6.3. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma
Other Applications
6.4. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Cancer Research Institutes
Specialty Clinics
Other End-Users
6.5. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Sub-Segmentation Of Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Self-Amplifying mRNA (saRNA)
Non-Replicating mRNA
Circular RNA (circRNA)-Based mRNA Therapy
6.6. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Sub-Segmentation Of Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemically Modified siRNA
Nanoparticle-Delivered siRNA
Conjugated siRNA
6.7. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Sub-Segmentation Of Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
miRNA Mimics
miRNA Inhibitors (Antagomirs)
miRNA Sponges Or Decoys
6.8. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Sub-Segmentation Of Other Therapy Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Long Non-Coding RNA (lncRNA)-Based Therapies
Short Hairpin RNA (shRNA)-Based Therapies
Aptamer-RNA Based Oncolytic Agents
7. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Regional And Country Analysis
7.1. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
9.1. China Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
9.2. China Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
10.1. India Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
11.1. Japan Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
11.2. Japan Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
12.1. Australia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
13.1. Indonesia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
14.1. South Korea Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
14.2. South Korea Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
15.1. Western Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
15.2. Western Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
16.1. UK Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.1. Spain Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
21.1. Eastern Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
21.2. Eastern Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
22.1. Russia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
23.1. North America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
23.2. North America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
24.1. USA Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
24.2. USA Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
26.1. South America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
26.2. South America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
27.1. Brazil Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
28.1. Middle East Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
28.2. Middle East Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
29.1. Africa Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
29.2. Africa Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Competitive Landscape And Company Profiles
